Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

LivaNova PLC today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14.

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...